Low-grade gliomas (LGG) constitute grades I and II tumors of astrocytic and grade II tumors of oligodendroglial lineage. Although these tumors are typically slow growing, they may be associated with significant morbidity and mortality because of recurrence and malignant progression, even in the setting of optimal resection. LGG in pediatric and adult age groups are currently classified by morphologic criteria. Recent years have heralded a molecular revolution in understanding brain tumors, including
G liomas constitute the most common primary central nervous system (CNS) tumor variants. The current World Health Organization (WHO) classification system uses 2 basic morphologic criteria to delineate individual diagnostic entities. The first defines tumor type on the basis of presumed histiogenesis into either astrocytic or oligodendroglial groupings. Further classification by grade, anticipating biological behavior in the absence of treatment, yields the final classification scheme: low-grade gliomas (LGGs)-(1) grade I astrocytomas: pilocytic astrocytomas, (2) grade II diffuse astrocytomas, and (3) grade II oligodendrogliomas; high-grade gliomas-(1) grade III anaplastic astrocytomas, (2) grade III anaplastic oligodendrogliomas, and (3) grade IV glioblastomas (astrocytic tumors). Additional morphologic subtypes, such as angiocentric glioma, have also been described, although their underlying pathogenesis remains relatively obscure.
The past decade has seen a molecular revolution driven by high-throughput sequencing technology, yielding penetrating insights into glioma pathogenesis. Several new driver mutations have been described in gliomas and the field has rapidly grown to reflect the emerging complexity of these tumors. Many of these insights carry prognostic and therapeutic implications and have impacted how we approach the diagnosis and classification of gliomas. As such, histopathologic criteria may no longer be solely sufficient to appropriately classify these tumors and it is increasingly recognized that molecular information should be integrated into standard diagnostic interpretations. 1 Although glioblastomas have undergone extensive genomic characterization, LGG remain comparatively less understood. In contrast to high-grade gliomas, LGG frequently exhibit extend periods of relative indolence in their growth and clinical behavior. Nevertheless, LGG that cannot be surgically resected are often associated with significant morbidity and mortality, with diffuse variants invariably progressing through recurrence to high-grade status. Thus, better molecular characterization of these tumors is critical to developing novel therapeutic targets for effective treatment. Recent years have witnessed significant advances in understanding the molecular characteristics of LGG. Moreover, although histopathologic features characterizing gliomas in adults and children are similar, it is becoming increasingly apparent that tumors in these 2 age groups have distinct underlying biological foundations. In this article, we review the various molecular alterations identified and characterized in pediatric and adult LGG and discuss the implications of recent discoveries from both diagnostic and biological perspectives.
MOLECULAR ASPECTS OF PEDIATRIC LOW-GRADE GLIOMAS
In recent years, findings from a number of studies have greatly clarified the molecular events likely driving pediatric gliomas. These discoveries include histone mutations in pediatric high-grade astrocytomas and alterations in BRAF, FGFR1, and MYB in astrocytic tumors. [2] [3] [4] [5] [6] [7] [8] [9] LGG are generally characterized by a lower frequency of somatic mutations and structural variations per tumor, suggesting that their pathogenesis is driven by fewer genetic changes overall. We discuss these molecular events below. As many of these findings represent new or relatively new discoveries, data regarding prognosis and potential mechanism of pathogenesis are just beginning to emerge.
BRAF Alterations in Low-grade Gliomas

BRAF-KIAA1549 Fusions
The most frequent alterations in pediatric LGG involve the v-raf murine sarcoma viral oncogene homolog B1 (BRAF proteins involved in the mitogen-activated protein (MAP) kinase pathway. Pilocytic astrocytomas (grade I) show tandem duplications at chromosome 7q34 resulting in the formation of a fusion gene between the kinase domain of BRAF and KIAA1549 (BRAF-KIAA1549 fusion gene). [4] [5] [6] [7] [8] [9] Rare BRAF fusions such as BRAF-FAM131B, BRAF-RNF130, BRAF-CLCN6, BRAF-MKRN1, and BRAF-GNAI1 have also been reported but at a much lower frequency. [9] [10] [11] Interestingly, pilocytic astrocytomas show variable rates of BRAF fusion depending on their location in the CNS. For example B75% of cerebellar pilocytic astrocytomas exhibit BRAF-KIAA1549 fusions. By contrast, only 33% of supratentorial and B50% of optic nerve pilocytic astrocytomas harbor BRAF fusions. [12] [13] [14] Data regarding the prognostic effects of BRAF fusion in pediatric LGG are variable, with no clear consensus, and thus may warrant further investigation. 12, 13, 15, 16 
BRAF V600E Mutation
Nonsynonymous point mutations in BRAF resulting in a valine to glutamic acid substitution at position 600 (V600E) were first described in melanocytic lesions. Subsequently, BRAF V600E mutations were identified in specific subtypes of gliomas. BRAF V600E mutations are most frequent in pleomorphic xanthoastrocytomas (B70%) and gangliogliomas (B20%) and occur at lower frequencies in pilocytic astrocytomas, diffuse astrocytomas, and pilomyxoid astrocytomas. 8, [17] [18] [19] [20] [21] BRAF V600E mutant LGG exhibited a trend toward increased risk for progression 16 and in gangliogliomas was associated with shorter recurrence-free survival. 22 
Receptor Tyrosine Kinase FGFR1 Alterations in Low-grade Gliomas
Receptor tyrosine kinase (RTK) are cell surface receptors that play a key role in signal transduction. These proteins bear an extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain (TKD), 23 and have been extensively implicated in the pathogenesis of both adult and pediatric high-grade glioma. 24 Two groups simultaneously reported LGG alterations in fibroblast growth factor receptor 1 (FGFR1), an RTK, and member of the FGF receptor family that binds to the fibroblast growth factor family of proteins. 8, 9 In diffuse cerebral LGG, intragenic duplications of a portion of the TKD of FGFR1 were noted in 24% of cases. 8 These alterations are thought to constitutively activate the receptor independent of ligand activation. Jones et al 9 reported mutations affecting the TKD of FGFR1 in 14/141 (2 sample sets including 5/96 and 9/45 tumors negative for BRAF alterations) pilocytic astrocytomas. Mutations involved 2 hotspot codons, Asn546 and Lys656. Moreover, FGFR1 mutant pilocytic astrocytomas tended toward extracerebellar and midline localization.
Interestingly, rare alterations involving the kinase domain of NTRK2 (TrkB), an RTK that binds BDNF, were noted in 2/49 pilocytic astrocytomas resulting in the formation of the fusion genes (QKI-NTRK2 and NACC2-NTRK2). 9 Similar to FGFR1 alterations, the fusion proteins include receptor dimerization domains and are hypothesized to dimerize independent of ligand.
MYB and MYBL1 Mutations in Low-grade Gliomas
MYB (V-Myb Avian Myeloblastosis Viral Oncogene
Homolog) copy number alterations were initially described in 2 diffuse astrocytomas (WHO grade II) and 1 angiocentric glioma (WHO grade II) using Affymetrix SNP arrays and interphase FISH analyses. 25 Subsequent efforts using whole genome sequencing, transcriptome, and targeted high-throughput sequencing showed rearrangement of MYBL1 (V-Myb Avian Myeloblastosis Viral Oncogene Homolog-Like 1) in 1 diffuse astrocytoma and rearrangement or copy number alterations of MYB in 5 diffuse astrocytomas, 2 angiocentric gliomas, and 1 oligodendroglioma. 8 Together, MYBL1 and MYB alterations were present in 25% of diffuse grade II LGG. Alterations in MYB manifested as episome formation, deletion of the negative-regulatory region of MYB, or deletion of micro-RNA-binding sites. 8 Another group identified gains on chromosome 8q13.1 involving MYBL1 in 28% (5/18) of pediatric diffuse astrocytomas, 26 where they resulted in tandem duplication and truncation of the negative-regulatory C-terminal domain of the protein. MYBL1 truncation products, but not wild-type MYBL1, when transduced into NIH-3T3 cells, were able to generate tumors in vitro in soft agar and as xenografts in vivo. Interestingly, this group did not identify MYB alterations in diffuse astrocytomas, although 2 angiocentric gliomas showed 6q23.3 deletions resulting in truncated MYB.
Genetic Alterations in BRAF and FGFR1 Give Rise to Aberrant Mitogen-activated Protein Kinase Pathway Signaling
The MAP kinase pathway is critical to normal development and deregulated in a multitude of cancers. Situated downstream of RTK activation, pathway signaling is initiated by recruitment of the G-protein Ras (through Shc and Sos), which in turn activates the Raf/MEK/ERK cascade, ultimately leading to protein phosphorylation and activation of multiple protein targets ( Fig. 1 ).
In the context of LGG, BRAF fusion proteins and the BRAF V600E mutation each result in aberrant activation of the MAP kinase pathway. BRAF fusion proteins bear the kinase domain, but not the autoinhibitory N-terminus and thus harbor constitutive kinase activity 27 (Fig. 1) . Similarly, intragenic duplications involving FGFR1 result in a constitutively active receptor protein, with downstream activation of the MAP kinase pathway. Indeed, expression of TKD-duplicated FGFR1 in vitro resulted in activation of the MAP kinase and phosphoinositide 3-kinase (PI3K) pathways and was reversed by FGFR1 inhibitors. Furthermore, Tp53-null astrocytes bearing TKD-duplicated FGFR1 when xenografted into mouse brains generated high-grade gliomas. The authors hypothesize that TKDduplicated FGFR1 brings 2 TKD together overriding the requirement for receptor dimerization by FGF for signal transduction. 8 That deregulated MAP kinase pathway signaling serves as a major driver in these tumors is underscored by the identification in LGG, albeit at lower frequency, of mutations in other core pathway components. For instance, mutations in the tyrosine phosphatase PTPN11 were noted in 2/49 pilocytic astrocytomas with FGFR1 mutations. 9 PTPN11 encodes a RAS-MAPK-related adapter protein, suggesting cooperativity with activating FGFR1 alterations ( Fig. 1 ). Along these lines, mutations in RAS and NF1 (encoding the neurofibromin protein, a negative regulator of RAS) were noted at similar frequencies. 8, 9 Together, these findings suggest that MAP kinase pathway activation is required for development of these tumors and, moreover, serves as a unifying pathogenic concept in the broad classification of well-encapsulated WHO grade I neuroepithelial neoplasms like pleomorphic xanthoastrocytoma, ganglioglioma, and pilocytic astrocytoma. Also consistent with these conjectures, conditionally deleted Mek1/2 significantly reduced glial progenitors in mice, leading to failed gliogenesis. Moreover, animals that survived to postnatal stages were nearly devoid of astrocytes and oligodendroglia. 28 Similarly, conditional deletion of ERK1/2 in mice resulted in abnormal glial development and reduced progenitor proliferation. 29 These factors underscore the importance of MAP kinase signaling in glial development and suggest that aberrant activation of this pathway mediates tumorigenesis in pediatric LGG.
MOLECULAR CHARACTERISTICS OF ADULT
LOW-GRADE GLIOMAS
IDH1/2 Mutations
The discovery of isocitrate dehydrogenase (IDH)1/2 mutations in gliomas heralded the genomic era of glioma research. Large profiling studies have identified IDH1/2 mutations in >70% of grades II and III gliomas and >90% of secondary GBM. [30] [31] [32] Wild-type IDH proteins form core components of the TCA cycle, where they catalyze the conversion of isocitrate to a-ketoglutarate (a-KG) in the cytoplasm (IDH1) and mitochondria (IDH2). IDH mutations are invariably missense and heterozygous, with IDH1 mutations predominating (> 90%), and involve active site arginine residues, either R132 in IDH1 or R172 in IDH2. [31] [32] [33] [34] Mutant IDH1/2 catalyze the generation of the oncometabolite D-2HG from a-KG 35, 36 (Fig. 2) , whose physiological effects are profound (see below). IDH-mutant gliomas tend to be occur more frequently in young adult patients. 31, 34, [37] [38] [39] Moreover, the association of IDH1/2 mutation with astrocytomas, oligodendrogliomas, and LGG). IDH1/2 mutations are thought to be an early event in adult LGG pathogenesis in a common precursor cell. Mutations in IDH1 (cytoplasmic) and IDH2 (mitochondrial) result in the generation of the oncometabolite 2-hydroxyglutarate (2HG). 2HG is thought to inhibit aketoglutarate-dependent demethylases resulting in histone and DNA-CpG island methylation (G-CIMP phenotype). Mutations in ATRX are seen in astrocytic tumors. ATRX is a helicase belonging to the SWItch/Sucrose NonFermentable family involved in H3.3 deposition (along with its partner DAXX). Its deficiency induces alternative lengthening of telomeres. 1p/19q codeletion is seen in oligodendrogliomas. CIC and FUBP1 alterations are associated with 1p/19q codeletion in a variable percentage of oligodendrogliomas. TERT promoter mutations are also noted in oligodendrogliomas and are thought to be important for telomere maintenance. Please see this image in color online.
Venneti and Huse
Adv Anat Pathol Volume 22, Number 2, March 2015 oligoastrocytomas strongly suggests that the event arises early in the pathogenesis of LGG 34, 37, 40 (Fig. 2) . IDHmutant tumors confer favorable prognosis relative to wildtype counterparts regardless of WHO grade. [41] [42] [43] [44] [45] A subset of gliomas exhibits widespread DNA hypermethylation across the genome, referred to as the CpG island hypermethylator phenotype (G-CIMP) 46 ). G-CIMP is strongly associated with mutations in IDH1/2 in LGG. [46] [47] [48] [49] [50] Moreover, in both immortalized astrocytes and colon cancer cell lines, expression of IDH1 R132H, the most common glioma-associated IDH mutation, fully recapitulates G-CIMP. 49, 50 The oncometabolite D-2HG generated in IDH-mutant tumors inhibits a variety of a-KG-dependent enzymes 51, 52 involved not only in DNA demethylation but also in carnitine synthesis, hypoxic sensing, collagen modifications, and histone modification (reviewed by Loenarz and Schofield 53 ). Indeed, astrocytic cell lines expressing mutant IDH1 R132H, and IDHmutant oligodendrogliomas show increased trimethylation of histone marks such as H3K9, H3K27, and H3K36 49,54,55 (Fig. 2) . Both DNA and histone hypermethylation, occurring as a consequence of elevated D-2HG, are thought to arrest cellular differentiation by repressing a broad spectrum of target genes 49, 54 (Fig. 2 ).
CIC and FUBP1 Mutations
Coincident whole-arm loss of chromosomes 1p and 19q is observed in approximately 70% of oligodendrogliomas and is a significantly favorable prognostic factor. [56] [57] [58] 1p/19q codeletion results from an unbalanced translocation involving the centromeric regions of chromosomes 1p and 19q 57 (Fig. 2) . Precisely how these genetic abnormalities contribute to oligodendroglial pathogenesis remains unestablished. However, it has been postulated for some time that these regions might harbor potential tumor-suppressor genes.
Mutations in CIC (homolog of the Drosophila gene capicua) on chromosome 19q and FUBP1 (FUSE-binding protein 1) on chromosome 1p have been recently described in oligodendrogliomas [59] [60] [61] [62] (Fig. 2) . CIC mutations were observed in 17% to 79% of tumors diagnosed at WHO grade II oligodendrogliomas (5/14, 59 7/9, 62 11/62, 60 8/21 61 ). This frequency rose to 25% to 75% when only 1p/19q codeleted tumors were considered (3/4, 59 7/9, 62 9/36, 60 7/12 63 ). Consistent with a loss-of-function phenotype, CIC mutations are distributed throughout the coding region of the gene (with a predilection for exon 5) and include nonsense, insertions/ deletions, missense, and frameshift variants. Also consistent with loss-of-fuction, FUBP1 mutations are mainly frameshift and nonsense variants, and occur at lower frequencies (14% to 22%) than CIC mutations in low-grade oligodendrogliomas (2/14, 59 2/9, 62 3/21, 61 3/17 63 ). CIC is known to functionally repress genes normally activated by RTK signaling by a mechanism called "default repression," 64 and FUBP1 is a DNA-binding protein that activates c-MYC transcription. 65 Thus, both CIC and FUBP1 appear to serve as negative regulators of established oncogenic pathways. Nevertheless, establishing the precise mechanisms by which either CIC or FUBP1 mutations contribute to oligodendroglioma pathogenesis will require further study.
ATRX Mutations
ATRX (a-thalassemia/mental retardation syndrome X-linked) is a DNA helicase and chromatin remodeling protein, belonging to the SWItch/Sucrose NonFermentable family. 66 Germline loss-of-function mutations in ATRX are associated with a-thalassemia mental retardation X-linked (ATRX) syndrome. 67 A primary function of ATRX is incorporation of histone H3.3 monomers into chromatin in collaboration with the histone chaperone protein DAXX (death-associated protein 6) 68, 69 (Fig. 2) . In 2012, ATRX mutations were described in adult and pediatric astrocytic gliomas 3, 61, [70] [71] [72] where they exhibited a strong association with the alternate lengthening of telomere phenotype, a pathologic telomere maintenance mechanism that promotes cellular immortality 3, 70, 73, 74 (Fig. 2) . In total, ATRX mutations were found in 33% to 67% of grade II astrocytic tumors, and occurred in 75% to 80% of IDH-mutant LGG that did not exhibit 1p/19q codeletion. 61, 70, 72 In fact, ATRX mutation was mutually exclusive with 1p/19q codeletion in glioma and strongly associated with TP53 mutation 3,61,70-72 (Fig. 2) . These data suggest that ATRX mutation, together with TP53 mutation, may delineate a distinct pathogenic route operative in the majority of diffuse astrocytic LGG. That being said, the precise mechanism(s) by which ATRX mutations drive gliomagenesis remain unclear.
TERT Promoter Mutations
Point mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene were first discovered in melanoma, and are thought to increase telomerase expression, thereby maintaining telomere length and enabling repeated cell division. 75, 76 These mutations have been identified in many CNS tumors, including glioblastomas, medulloblastomas, and LGG. They occur exclusively at positions À228 and À250 in the TERT promoter region, substituting a cytosine for a thymine in either case to unmask a binding site for ETS family transcription factors. [77] [78] [79] [80] [81] In LGG, TERT promoter mutations are predominantly observed in oligodendrogliomas (63% to 78%, 12/19 77 ; 25/ 34 78 ; and 29/37 82 ) and less frequently (0% to 32%) in diffuse astrocytomas (0/8, 77 10/52, 78 8/25 82 ) . Intriguingly, astrocytic tumors with TERT promoter mutations show an inverse relationship with IDH mutations. 82 In addition, TERT promoter mutations are tightly associated (98% to 100%) with 1p/19q codeletion and are mutually exclusive with ATRX mutations in LGG [77] [78] [79] 82 (Fig. 2) . These findings emphasize the importance of pathologic telomere maintenance in LGG, whether by way of TERT promoter mutations in 1p/19q codeleted tumors (predominantly oligodendroglioma), or alternate lengthening of telomere in ATRX-mutant tumors (predominantly astrocytoma).
DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS OF MOLECULAR GENETICS IN PEDIATRIC AND
ADULT LOW-GRADE GLIOMAS
Diagnostic Implications
As detailed above, high-throughput molecular profiling has dramatically altered conceptions of glioma biology and, in doing so, has led to refinements of well-established classification schemes (Figs. 1, 2) . Perhaps most notably, the identification of IDH1/2 mutations in both low-grade and high-grade adult gliomas is now of considerable importance, due to the significant prognostic benefit conferred by the genomic alteration. The standard initial approach of many pathology practices is immunohistochemical, using an antibody specifically directed against IDH1 R132H (accounting for >95% of all glioma-associated IDH mutations), followed by sequencing-based genotyping in immunonegative cases. The availability of a robust immunohistochemical reagent recognizing most IDH-mutant tumors also facilitates the differentiation of true glial neoplasms from non-neoplastic glioma mimics such as reactive astrogliosis. 33, [83] [84] [85] [86] [87] The mutual exclusivity of ATRX mutation and 1p/19q codeletions in LGG has prompted the proposal that all diffuse gliomas be classified on the basis of IDH and ATRX mutational status-or a negative staining pattern by IHC (Fig. 3A) -combined with 1p/19q codeletion. This approach may lend better clarity to the often-subjective diagnosis of mixed lineage gliomas (oligoastrocytomas), as these tumors have been shown to nicely segregate into ATRX-mutant and 1p/19q codeleted subgroups. 61, 70, 72 Moreover, prognostic stratification among gliomas delineated by these molecular criteria outperforms that seen following conventional histopathologic classification. 61, 88 CIC and FUBP1 mutations do not bear 100% concurrence with 1p/19q codeletions. [59] [60] [61] [62] Thus, from a diagnostic and prognostic view, assessment of 1p/19q deletion remains superior to CIC and FUBP1 genotyping in the establishment of oligodendroglial lineage. As an aside, the near universal occurrence of TERT mutations in 1p/19q codeleted LGG suggests that combined IDH1/2 and TERT genotyping might also support the rendering of an oligodendroglioma diagnosis. 77 In pediatric LGG, the identification of BRAF alterations-by molecular techniques or the BRAF V600E antibody (Fig. 3B )-is of significance due to the potential for targeted therapies (see below). Identifying BRAF alterations may also help in diagnostically challenging cases by designating encapsulated WHO grade I astrocytic variants (eg, pilocytic astrocytoma) from other neoplastic entities. 19, 89 That being said, more studies are required to fully assess the impact of BRAF, FGFR1, and MYB/MYBL1 alterations on current classification of pediatric LGG.
Therapeutic Implications
The advances in the molecular characterization of LGG discussed above have provided numerous insights into potential pathogenic mechanisms. Indeed, these studies have yielded an array of therapeutic targets that can be leveraged to design novel therapies. Many of these efforts are still in experimental stages. However, pharmaceutically targeting BRAF V600E has already achieved considerable success in melanoma [90] [91] [92] and V600E inhibitors were effective in preclinical animal models of high-grade glioma 93, 94 and a single case of a 12-year-old patient with GBM. 95 However, these successes should be treated with cautious optimism because of the established existence of multiple mechanisms of resistance to BRAF inhibitors in other tumor types. 96 Recent studies have also shown that mutant IDH1 inhibition is partially effective in xenograft glioma models, although blood-brain barrier permeability remains an issue. 97 Alternatively, vaccine-based approaches against IDH1 R132H have elicited antitumor immune responses in tumors bearing the mutation. 98 The utility of these and other therapeutic strategies in targeting LGG remains unclear and will be the subject of extensive research effort in the immediate future.
